c-Myc shRNA Plasmid (h) from Santa Cruz Biotechnology, Inc.

Product Specs
Itemc-Myc shRNA Plasmid (h)
CompanySanta Cruz Biotechnology, Inc.
Price $592.00Supplier Page View Company Product Page
Catalog Numbersc-29226-SH
Quantity20 µg
RNA TypeshRNA Clones
Vector Type (Standardized)Lentiviral
TypeshRNA Plasmid
Specieshuman
NCBI Full Gene NameMYC proto-oncogene, bHLH transcription factor
NCBI Gene AliasesMRTL, MYCC, bHLHe39, c-Myc

Add to Compare List

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancerJournal of Experimental MedicineNovember 4, 2024Zhen Chen, Karin A. Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang, Ticiana Leal, Suresh S. Ramalingam, Shi-Yong SunsiRNA (sc-36641), hTERT shRNA plasmid (sc-36641-SH), c-Myc siRNA (sc-29226), and c-Myc shRNA plasmid (sc-29226-SH) were purchased from Santa Cruz Biotechnology. Scrambled control siRNA and the procedures used for transfection

(2) mTORC1-c-Myc pathway rewires methionine metabolism for HCC progression through suppressing SIRT4 mediated ADP ribosylation of MAT2ACell & bioscienceNovember 12, 2022Zhao L, Su H, Liu X, Wang H, Feng Y, Wang Y, Chen H, Dai L, Lai S, Xu S, et al.α-pan-ADP-Ribose binding reagent (MABE1016) was purchased from Merck. Cell transfection c-Myc shRNA (sc-29226-SH), TRIM32 siRNA (sc-61714), TRIM32 shRNA (sc-61714-SH), SIRT4 shRNA (sc-63024-SH), MAT2A shRNA (sc-106203-SH)

(3) Argininosuccinate lyase drives activation of mutant TERT promoter in glioblastomasMolecular cellOctober 20, 2022Shi Z, Ge X, Li M, Yin J, Wang X, Zhang J, Chen D, Li X, Wang X, Ji J, et al.

(4) c-Myc Sustains Pancreatic Cancer Cell Survival and mutp53 Stability through the Mevalonate PathwayBiomedicinesOctober 5, 2022Romeo MA, Gilardini Montani MS, Arena A, Benedetti R, D'Orazi G, Cirone M.

(5) PLEK2 promotes cancer stemness and tumorigenesis of head and neck squamous cell carcinoma via the c-Myc-mediated positive feedback loopCancer communications (London, England)October 1, 2022Zhao X, Shu D, Sun W, Si S, Ran W, Guo B, Cui L.

(6) Transcription factor AP2 enhances malignancy of non-small cell lung cancer through upregulation of USP22 gene expressionCell communication and signaling : CCSSeptember 19, 2022Sun T, Zhang K, Li W, Liu Y, Pangeni RP, Li A, Arvanitis L, Raz DJ.

(7) KRT13 promotes stemness and drives metastasis in breast cancer through a plakoglobin/c-Myc signaling pathwayBreast cancer research : BCRJanuary 25, 2022Yin L, Li Q, Mrdenovic S, Chu GC, Wu BJ, Bu H, Duan P, Kim J, You S, Lewis MS, et al.

(8) DNA damage triggers an interplay between wtp53 and c-Myc affecting lymphoma cell proliferation and Kaposi sarcoma herpesvirus replicationBiochimica et biophysica acta. Molecular cell researchJanuary 1, 2022Arena A, Gilardini Montani MS, Romeo MA, Benedetti R, Gaeta A, Cirone M.

(9) TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivityInternational journal of biological sciencesJanuary 1, 2022Liu Q, Chung S, Murata MM, Han B, Gao B, Zhang M, Lee TY, Chirshev E, Unternaehrer J, Tanaka H, et al.

(10) Knockdown of c-MYC Controls the Proliferation of Oral Squamous Cell Carcinoma Cells in vitro via Dynamic Regulation of Key Apoptotic Marker GenesInternational journal of molecular and cellular medicineDecember 1, 2021Sabit H, Tombuloglu H, Cevik E, Abdel-Ghany S, El-Zawahri E, El-Sawy A, Isik S, Al-Suhaimi E.

(11) Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer CellsCellsSeptember 12, 2021Steifensand F, Gallwas J, Bauerschmitz G, Gründker C.

(12) The chromatin modifier MORC2 affects glucose metabolism by regulating the expression of lactate dehydrogenase A through a feed forward loop with c-MycFEBS lettersMay 1, 2021Guddeti RK, Thomas L, Kannan A, Karyala P, Pakala SB.

(13) P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9Neoplasia (New York, N.Y.)March 1, 2021Tian X, Ahsan N, Lulla A, Lev A, Abbosh P, Dicker DT, Zhang S, El-Deiry WS.

(14) SOX2-dependent expression of dihydroorotate dehydrogenase regulates oral squamous cell carcinoma cell proliferationInternational journal of oral scienceJanuary 29, 2021Qiu X, Jiang S, Xiao Y, He Y, Ren T, Jiang L, Liu R, Chen Q.

(15) Nucleolar c-Myc recruitment by a Vibrio T3SS effector promotes host cell proliferation and bacterial virulenceThe EMBO journalJanuary 15, 2021Hu M, Zhang Y, Gu D, Chen X, Waldor MK, Zhou X.

(16) Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal CancerFrontiers in pharmacologyJanuary 1, 2021Hassan MS, Cwidak N, Johnson C, Däster S, Eppenberger-Castori S, Awasthi N, Li J, Schwarz MA, von Holzen U.

(17) All-trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down-regulating B7-H6 expression via c-Myc signalingCancer communications (London, England)January 1, 2021Cao G, Cheng Y, Zheng X, Wei H, Tian Z, Sun R, Sun H.

(18) Targeting CLK3 inhibits the progression of cholangiocarcinoma by reprogramming nucleotide metabolismThe Journal of experimental medicineAugust 3, 2020Zhou Q, Lin M, Feng X, Ma F, Zhu Y, Liu X, Qu C, Sui H, Sun B, Zhu A, et al.

(19) Mechanisms of site-specific dephosphorylation and kinase opposition imposed by PP2A regulatory subunitsThe EMBO journalJuly 1, 2020Kruse T, Gnosa SP, Nasa I, Garvanska DH, Hein JB, Nguyen H, Samsøe-Petersen J, Lopez-Mendez B, Hertz EPT, Schwarz J, et al.

(20) Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human OsteosarcomaInternational journal of molecular sciencesJune 24, 2020Godel M, Morena D, Ananthanarayanan P, Buondonno I, Ferrero G, Hattinger CM, Di Nicolantonio F, Serra M, Taulli R, Cordero F, et al.

Be the First to Write a Review!